You are currently browsing the daily archive for October 29, 2013.

Pierre Omidyar: from eBay to Philanthropy

By Shlomo Maital   


Pierre Omidyar is well known as the pioneering founder of eBay.  That company, after it was acquired, made him immensely wealthy; by the time he was 30 he was a billionaire.  Today, he is 46,  and he is deploying fully $1 b. of his fortune for philanthropy.  But unlike Jeff Bezos, founder of Amazon, who spent $250 m. to buy the Washington Post,  Omidyar is spending $250 m. to revolutionize the media.

  According to the Economist (the Schumpeter column),  “… in 2004 Mr Omidyar replaced his foundation with a new organisation, Omidyar Network, which sees itself as an active investor, not a passive donor, and is free to put money equally into for-profit and non-profit ventures. Almost half of the 300 or so outfits it has backed aimed to make money—though Mr Omidyar has said that any profits will be recycled, with none going back to him.”  

   The Economist continues:   “With the non-profits it backs, ranging from Kiva, a microfinance website, to the Sunlight Foundation, which promotes open government, Omidyar Network practises “venture philanthropy”—developing a non-profit start-up in the same way as a new business venture, except for not expecting it to make money one day. Typically, foundations have given funds for a specific project rather than to build the capabilities of the charity itself, which makes it hard for the charity to hire and retain talented people. In contrast, the network not only provides money for its charities’ general budget, it has a human-resources department that helps them find good staff. This service seems to be universally appreciated by the charities Mr Omidyar backs, some of which say it is more valuable than the money they get. Although there are several other successful venture-philanthropy organisations, such as New Profit Inc (which helped develop the Teach for America charity), none comes close to the scale of Omidyar Network, which makes it the crucial test case for the idea.”

      Omidyar ‘invented’ on-line commerce. Now he seeks to reinvent philanthropy.   He seems to have put his finger on a key failing of many social enterprises – good management, proper staffing.  We wish him well.


From Basic Biological Science to Market Success:

How Bob Langer Changes the World

By Shlomo Maital   


Bob Langer is a renowned MIT scientist.  His famous lab has generated an endless stream of inventions that benefit mankind, including radical new methods for controlled-release drug delivery.  This is important – when we swallow a pill, the concentration of the drug in our blood rises, then falls, then rises again when we take another.  Controlled-release technology keeps the level of the drug constant, in our blood stream, so that it is more effective. 

   Prof. Langer shared his ‘secret of success’ in a recent article in Nature Biotechnology, 31 (6), June 2013.  It includes 3  “P’s”:   platform, paper, patent.

   * Platform:  develop a technology that can be used over and over in different applications and technologies. E.g., his method for controlled release drug delivery systems also found use in microspheres for food applications, e.g. fat substitutes.

   *  Paper:  Publish your results in a high profile journal;  “peer review validates the idea”.  You can of course file for a patent within a year of publishing the paper.

   *  Patent:  “ideally, file a blocking patent, that protects the platform, and all the ways it can be used and applied”. 

    Platform, paper and patent – all persuade investors of the validity of the idea.  Add to this two more P’s:   P of P,  proof of principle —   show the technology is viable.   Speed is vital, adds Langer; the more rapidly you can get to clinical trials, the better.  And you need a champion.  Langer’s champions are his doctoral students, who develop technologies in their Ph.D. theses, then go on to found companies. Langer often serves on the board, makes introductions, helps get financing.  Langer himself is a bench scientist, and focuses exclusively on scientific research.  But his vision has led to many many spin-off companies emerging from his lab.  At a time when many biotech startups fail, Langer appears to have developed a winning formula.  If I were in biotech, I would study the Langer Lab formula closely.

Blog entries written by Prof. Shlomo Maital

Shlomo Maital
October 2013